Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899087 · ClinicalTrials.gov registry record
DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis
A clinical trial of Acute Pancreatitis, sponsored by University of Minnesota.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06899087: Recruiting study of Acute Pancreatitis, sponsored by University of Minnesota.
NCT06899087 is a study of Acute Pancreatitis that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 45 participants, below the 2,314-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06899087, a study of Acute Pancreatitis, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to identify novel blood-based biomarkers for prediction and diagnosis of infected pancreatic necrosis (IPN) in patients with necrotizing pancreatitis (NP). Acute pancreatitis (AP) is the leading cause of gastrointestinal hospital admissions, accounting for over 300,000 emergency department visits annually and imposing a significant socio-economic burden. It is an acute inflammatory condition of the pancreas characterized by damage to the acinar cells, which triggers an inflammatory response and causes widespread systemic damage. In about 20% of cases, the disease progresses to necrotizing pancreatitis (NP), a severe form characterized by tissue necrosis. NP poses serious health risks, especially when the necrotic tissue becomes infected, leading to infected (peri-)pancreatic necrosis (IPN), which is associated with secondary organ failure (OF), sepsis, and mortality rates as high as 40%. While patients with sterile (peri-)pancreatic necrosis (SPN) can often be managed conservatively, those with IPN typically require antibiotics and therapeutic interventions such as endoscopic drainage or surgery. Timely recognition and treatment of IPN are crucial for improving patient outcomes, yet current diagnostic methods based on clinical symptoms and routine lab markers lack the specificity to reliably distinguish SPN from IPN in the early stages. Furthermore, while multifactorial scoring systems like Ranson, Imrie, and APACHE II predict necrosis and overall severity in AP, they are not accurate for identifying IPN or predicting mortality in NP. The diagnostic gap delays appropriate treatment, allowing the infection to advance and limiting available therapeutic options. The growing incidence and significant impact of AP and NP in the general population underscore the urgent need to better understand IPN pathophysiology and to develop specific diagnostic biomarkers that can improve prognosis, guide therapeutic decisions, and enhance patient outcome
Primary Outcome
by assessing pro- and anti-inflammatory cytokines, immune response of peripheral blood mononuclear cells (PBMCs), and plasma metabolites
Conditions Studied
Interventions
- OTHER not interventional
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2026-12-01 |
What NCT06899087 shows while recruiting
NCT06899087 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 2,314-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Acute Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which not interventional is the first listed.
NCT06899087 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06899087 about?
NCT06899087 is a clinical study titled "DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis". The purpose of the study is to identify novel blood-based biomarkers for prediction and diagnosis of infected pancreatic necrosis (IPN) in patients with necrotizing pancreatitis (NP). Acute pancreatitis (AP) is the leading cause of gastrointestinal hospital admissions, accounting for over 300,000 e...
What is the current status of trial NCT06899087?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2025-07-01. Estimated completion is 2026-12-01.
What conditions does trial NCT06899087 study?
This clinical trial studies the following conditions: Acute Pancreatitis.
What interventions are being tested in trial NCT06899087?
The interventions under investigation include: not interventional (OTHER).
Who is sponsoring clinical trial NCT06899087?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899087 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06899087's enrollment target sits among peer trials
45 7th of 10 higher than 4 of 10 other Acute Pancreatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
iMmune SignAtures and Clinical outComes in AP
RECRUITING
-
Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections
RECRUITING
-
Necrosectomy With Cryotechnology for Accelerated Removal
RECRUITING · NA
-
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
RECRUITING
-
Diabetes RElated to Acute Pancreatitis and Its Mechanisms
RECRUITING
-
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI